sponsored
PatientsVille.com Logo

PatientsVille

American Trypanosomiasis Medical Research Studies

Up-to-date List of American Trypanosomiasis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest American Trypanosomiasis Medical Research Studies

Rank Status Study
1 Unknown  Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease
Conditions: Chagas Disease;   Lactation
Intervention:
Outcome Measures: Nifurtimox concentration in breastmilk and in plasma;   Incidence of adverse drug reactions in women treated with nifurtimox during lactation
2 Unknown  Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease
Conditions: Chagas Disease;   Lactation
Intervention:
Outcome Measures: Benznidazole concentration in breastmilk and in plasma;   incidence of adverse drug reactions in women treated with benznidazole during lactation
3 Recruiting MicroRNAs as Biomarkers in Patients With Chagas Disease
Condition: Chagas Disease
Intervention:
Outcome Measures: Correlation of plasmatic levels of MicroRNAs with the percentage of heart fibrosis;   Correlation of plasmatic levels of MicroRNAs with the functional cardiovascular capacity;   Correlation of plasmatic levels of MicroRNAs with the left ventricular function;   Correlation of plasmatic levels of MicroRNAs with the serum levels of Pro-BNP.;   Correlation of plasmatic levels of MicroRNAs with the serum levels of TNF-alpha;   Correlation of plasmatic levels of MicroRNAs with the serum levels of IFN-gamma.
4 Recruiting Syndecan-4 as a Biomarker in Patients With Chagas Disease
Condition: Chagas Disease
Intervention:
Outcome Measures: Correlation of plasmatic levels of syndecan-4 with the percentage of heart fibrosis;   Correlation of plasmatic levels of syndecan-4 with the functional cardiovascular capacity;   Correlation of plasmatic levels of Syndecan-4 with the left ventricular function;   Correlation of plasmatic levels of Syndecan-4 with the serum levels of Pro-BNP.;   Correlation of plasmatic levels of Syndecan-4 with the serum levels of TNF-alpha;   Correlation of plasmatic levels of Syndecan-4 with the serum levels of IFN-gamma.
5 Recruiting Galectin-3 as a Biomarker in Patients With Chagas Disease
Condition: Chagas Disease.
Intervention:
Outcome Measures: Correlation of plasmatic levels of Galectin-3 with the percentage of heart fibrosis;   Correlation of plasmatic levels of Galectin-3 with the functional capacity of the heart;   Correlation of plasmatic levels of Galectin-3 with the serum levels of Pro-BNP.;   Correlation of plasmatic levels of Galectin-3 with the serum levels of TNF-alpha;   Correlation of plasmatic levels of Galectin-3 with the serum levels of IFN-gamma.
6 Recruiting New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease
Condition: Chagas Disease
Intervention: Drug: Benznidazole
Outcome Measures: Biomarkers for prognosis, early diagnosis and effectiveness of treatment.;   Cardiac function after antiparasitic treatment
7 Recruiting Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
Conditions: Heart Failure;   Heart Failure, Systolic;   Chagas Disease;   Chagas Cardiomyopathy
Intervention: Device: transcatheter renal denervation
Outcome Measures: Composite: death, myocardial infarction, cerebrovascular event, need of intervention on renal arteries and renal function impairment (decrease in estimated GFR > 30% from baseline).;   Left Ventricular Ejection Fraction (LVEF) by echocardiography.;   New York Heart Association (NYHA) functional class.;   6-minute walk test;   Peak Oxygen consumption (VO2) by ergoespirometry.
8 Recruiting Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS)
Condition: Chagas Disease With Heart Failure
Intervention: Drug: Aspirin
Outcome Measures: Brain magnetic resonance imaging lesions;   Biomarkers;   Proportion of high intensity transient signals on transcranial Doppler monitorization
9 Recruiting Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease
Conditions: Chagas Disease;   Heart Diseases
Interventions: Device: Implantable Cardiac Monitor;   Procedure: Standard of Care
Outcome Measures: To compare the time to the physician's decision to treat for electrical disorders (brady/tachyarrhythmias) between the two randomized groups.;   Summarize the recorded arrhythmic events stored within the ICM (bradyarrhythmia and tachyarrhythmia.;   Compute the time duration spent in arrhythmias for ICM patients.;   Compute the incidence of symptomatic arrhythmias in patients with an ICM;   Compare the time to the physician's decision to treat with components of the composite primary endpoint between randomization arms.;   Compare the mortality rate between randomization arms.
10 Unknown  Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease
Condition: Chronic Chagas Disease, Indeterminate
Interventions: Drug: E1224;   Drug: Benznidazole;   Drug: Placebo
Outcome Measures: Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment;   Consistently negative serial qualitative PCR as a measure of sustained parasitological eradication;   Qualitative PCR as a measure of parasite eradication;   Quantitative PCR as a measure of change in parasite load over time;   Incidence of serological conversion to negative and changes in titers over time as measured by conventional and non-conventional serologies;   Changes in the levels of biomarkers over time: brain natriuretic peptide, troponin T, selected prothrombotic factors, lytic antibodies, apolipoprotein A1 and multiplex serodiagnostic assay;   Area under the plasma concentration versus time curve (AUC), Peak Plasma Concentration (Cmax), Minimum Plasma Concentration (Cmin), Clearance, Volume of Distribution , and Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole;   Incidence and severity of adverse events (clinical and laboratory);   Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation;   Early and late predictors of sustainable response to treatments;   Correlation of pharmacokinetic parameters with parasitological response, changes in biomarkers and safety outcomes
11 Unknown  Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Condition: Chagas Disease
Intervention: Procedure: Trypanosoma cruzi serology
Outcome Measure: Prevalence of positive trypanosoma cruzi serologies
12 Unknown  BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
Conditions: Chagas Disease;   Trypanosomiasis;   Heart Disease
Interventions: Drug: Benznidazole;   Drug: Placebo
Outcome Measures: It will also evaluate the cardiovascular events of the large outcome trial, the first occurrence of any of the following clinically significant outcomes: Death;   Resuscitated cardiac arrest, requiring defibrillator or cardioversion;   Documented sustained ventricular tachycardia requiring cardioversion;   New development of symptomatic congestive heart failure;   Pacemaker or implantable cardiac defibrillator implantation;   Stroke or any other thromboembolic event in patients with no prior thromboembolic phenomena;   Heart Transplant;   New development of any of the following echo changes clinically indicated or done for the trial: Segmental wall motion abnormalities;   Ventricular aneurysm;   Reduction in left ventricular (LV) ejection fraction > 5%;   Increase in left ventricular diastolic dysfunction (LVDD) > 5.0 mm compared with baseline;   New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.);   Progression of New York Heart Association (NYHA) functional class by at least one category;   Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment;   To determine the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR.;   Safety and tolerability of benznidazole
13 Recruiting Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction
Condition: Chagas Disease
Intervention: Other: Exercise
Outcome Measures: Sympathetic nerve activityAutonomic control;   Peak oxygen consumption;   Skeletal muscle strength
14 Not yet recruiting A Prospective, Phase II Clinical Trial for Evaluation of G- CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy
Condition: Chronic Chagasic Myocarditis
Interventions: Drug: Treatment with G-CSF (Granulocyte colony stimulating factor);   Drug: Placebo saline
Outcome Measures: NYHA (New York Heart Association) functional class improvement;   Assessment of cardiovascular function measured by transthoracic echocardiography;   Assessment of cardiovascular function measured by cardiac magnetic resonance imaging;   Evaluation of functional capacity assessed by treadmill test and by 6-minute walk test;   Evaluation of improvement of quality of life;   Determination of tolerability
15 Recruiting Improving Blood Safety and HIV Testing in Brazil
Conditions: HIV;   Herpes Simplex 2;   Hepatitis C;   Hepatitis B;   Chagas Disease
Interventions: Behavioral: HIV Counseling and Testing;   Behavioral: Blood Donation
Outcome Measures: HSV-2 Prevalence in Blood Donors;   Intervention Impact in Blood Donors;   Prevalence of Transfusion-Transmitted Infections in Blood Donors
16 Recruiting Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias
Conditions: Ventricular Tachycardia;   Sudden Death;   Syncope;   Chest Pain
Intervention: Procedure: Catheter ablation
Outcome Measures: Evaluate the feasibility of mapping and ablating ventricular tachycardias in endocardial and epicardial using a contact force catheter;   Evaluate the impedance and voltage threshold for scar in chronic chagasic cardiomyopathy
17 Recruiting Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy
Condition: Chagas Cardiomyopathy
Interventions: Dietary Supplement: Omega-3;   Dietary Supplement: Placebo Comparador
Outcome Measures: Cytokine profile;   Lipid profile
18 Recruiting Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease
Condition: Chagas Heart Disease
Interventions: Other: Standard care and Pharmaceutical care;   Other: Standard care
Outcome Measures: Quality of life.;   Incidence and types of drug-related problems;   Physical functional capacity.
19 Recruiting Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection
Condition: Parasitic Disease
Intervention:
Outcome Measures: To evaluate, treat and follow patients with parasitic infections not covered by existing LPD/NIAID protocols;   To screen patients with suspected parasitic infections for enrollment on other LPD/NIAID protocols
20 Unknown  Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Condition: Dilated Cardiomyopathy
Interventions: Biological: CD34+ autologous stem cell transplantation;   Drug: Bone Marrow Stimulation
Outcome Measures: Heart failure mortality;   Changes in exercise capacity;   Changes in electrophysiologic properties of ventricular myocardium;   Changes in plasma inflammatory markers;   Changes in left ventricular function

These studies may lead to new treatments and are adding insight into American Trypanosomiasis etiology and treatment.

A major focus of American Trypanosomiasis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss American Trypanosomiasis